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Abstract 
Isomeric analogs of cyclobrassinin phytoalexin possessing the 1,3-thiazino[5,6-b]indole-4-one skeleton have been 
prepared. Starting from 1H-indole-2-carbonyl isothiocyanate, N-aryl-N’-(indole-2-carbonyl)-substituted thiourea or the 
corresponding S-aryl-N-(indole-2-carbonyl)dithiocarbamate intermediates were prepared and then transformed by ring-
closure via Hugerschoff reaction with phenyltrimethylammonium tribromide. Attempted synthesis of N’-(indole-2-
carbonyl)-N-(3,4,5-trimethoxyphenyl)thiourea unexpectedly delivered the 2-(indole-2-carbonylamino)-5,6,7-trimethoxy-
benzothiazole ring system. The structures of the new ring systems were determined by means of IR and NMR 
spectroscopy. The new derivatives synthesized exert moderate in vitro antiproliferative effects on a panel of adherent 
human cell lines (HeLa, A2780, A431 and MCF7). 
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Introduction 
 
Among the possible isomers of 1,3-thiazinoindoles condensed at bond b of the indole skeleton, the most 
interesting derivatives are 1,3-thiazino[6,5-b]indoles. Compounds possessing this ring system, such as 
cyclobrassinin and their biosynthetic or synthetic precursors (brassinin), belong to the family of natural 
phytoalexins and were isolated from cruciferous plants, first from Chinese cabbage (Figure 1).1 
 Phytoalexins are antimicrobial substances of low molecular weight produced by plants in response to 
infection or stress, which form part of their active defense mechanisms, probably as a result of the de novo 
synthesis of enzymes, as a part of the immune system of plants.2 In addition to their antimicrobial activities, 
brassinin and cyclobrassinin have various other pharmacological effects. They inhibit the formation of 
preneoplastic mammary lesions in culture.3 They also exerts in vitro antiproliferative effect on a number of 
different human cell lines.4,5 As for the pharmacodynamic mechanism, brassinin and its derivatives are 
inhibitors of indolamine 2,3-dioxygenase, a new cancer immunosuppression target.6 Izutani et al. revealed, 
that brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the 
phosphatidylinositol 3-kinase signalling pathway in human colon cancer cells.7 Kello et al. investegated ROS-
dependent antiproliferative effect of homobrassinin, a brassinin derivative, in human colorectal cancer caco2 
cells.8 Lee et al. showed that brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and 
SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel.9 
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Figure 1 
 
 Extensive investigations have been focused on the natural members of S,N-phytoalexins from 
antiproliferative point of view. In contrast, relatively few isomeric bioisoster indole compounds of this type 
were sythesized and investigated from pharmacological aspects. A series of 2-alkyl- or 2-arylimino-1,3-
thiazino[5,4-b]indol-4-one derivatives10 inhibits human leukocyte elastase and α-chymotrypsin. The 4-oxo-1,3-
thiazino[6,5-b]indole derivatives of cyclobrassinone were prepared Kutschy et al. It turned out later, however, 
that the original structure of this phytoalexin was most probably misinterpreted.11 
 In our previous work we prepared isobrassinin (1), 2-methylthio-1,3-thiazino[5,6-b]indole 
(isocyclobrassinin, 2, X = S, R = Me, Figure 1) and its 2-benzylthio- analog 2 (X = S, R = Bn, Figure 1) and found 
them to exert good in vitro antiproliferative effects on cervical adenocarcinoma (HeLa), breast 
adenocarcinoma (MCF7) and squamous skin carcinoma (A431) cell lines.5 For the investigation of structure–
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activity relationships, further 2-aryl-1,3-thiazino[5,6-b]indole analogs were synthesized. The highest cytotoxic 
effect was displayed by 2-phenylimino-1,3-thiazino[5,6-b]indole 2 (X = N, R = Ph, Figure 1), which 
demonstrated inhibitory activity on the above three cell lines comparable to that of cisplatin.5 
 In order to improve the possible efficacy our attention next turned to the incorporation of indol-2-
carboxamide moiety (3, 4; Figure 1) into isobrassinin and isocyclobrassinin analogon compounds (1, 2; Figure 
1). Motifs containing the indole-2-carboxamide moiety have the increased ability to bind to different receptors 
and enzymes. Compounds containing this pharmacophore, therefore, can be found in varied biologically active 
compounds. Certain derivatives, which target allosteric modulation of cannabnoid receptor 1 (CB1),12 
glycogene phosphorylase inhibitors,13 neurotensin (NT) (8–13) mimetics,14 monoamine oxidase inhibitors,15 
agonists of nociceptin/orphanin FQ (N/OFQ receptors,16 dopa D3 receptor,
17 selective antagonists of NR2B 
subunit containing N-methyl-D-aspartate (NMDA) receptor,18 can be useful in different mental and CNS 
disorders. Furthermore, other indole-2-carboxamide counterparts may act as antioxidants,19 coagulation 
factor Xa inhibitors20 and can have useful in different pathological conditions, such as heart failure 
conditions,21 diabetes,22 osteoporosis,23 Chron’s dishease,24 and certain infections.25 These are also inhibitors 
of different enzymes (Rho kinase,26 endothelin-converting enzyme,27 vascular endothelial growth factor FR2 
VEGFR2 tyrosine kinase,28 topoisomerase I,29 type 5 17β-hydroxysteroid dehydrogenase,30 tubulin 
polimerization31), may act as apoptosis inducers32 and potential DNA-intercalating compounds33 (like 
duocarmycin A). In addition, they exert promising and remarkable in vitro antiproliferative effects. 
     Subsequent to our recent investigations on 1,3-thiazinoindole derivatives5,34-36 and the chemistry of sulfur- 
and nitrogen-containing heterocycles with condensed skeleton,37 we set out to investigate the synthesis, 
structure and in vitro antiproliferative effect of new 1,3-thiazino[5,6-b]indole-4-one derivatives and their 
intermediates. 
 
 
Results and Discussion 
 
Our starting material 1H-indole-2-carbonyl isothiocyanate 7 was obtained from 1H-indole-2-carboxylic acid (5) 
(Scheme 1). Treatment of 5 with thionyl chloride in tetrahydrofuran provided 1H-indole-2-carbonyl chloride 
(6), which was reacted with potassium thiocyanate in acetone at room temperature. The reaction furnished 
isothiocyanate 7, which was used in the next step without any further purification (Scheme 1). 
 The key intermediate N,N’-disubstituted thioureas 9a–c were synthesized form acyl isothiocyanate 7 by its 
reaction with substituted aniline derivatives 8a–c in acetone in good yields (Scheme 1). According to our 
previous results for the preparation of our target 1,3-thiazino[5,6-b]indole-4-one derivatives, the Hugerschoff 
reaction was applied. The oxidative cyclization of (4-chlorophenyl)thiourea derivative 9a with 
phenyltrimethylammonium tribromide in dichloromethane yielded thiazinoindole 10. It turned out, however, 
that this compound exists as an equilibrium mixture of tautomers 10-endo and 10-exo in 
hexadeuterodimethyl sulfoxide under NMR measuring conditions. 
 4-(Ethoxycarbonyl)phenyl-substituted thiourea 9b gave the excepted 2-[4-(ethoxycarbonyl)phenylimino]-
1,3-thiazino[5,6-b]indole-4-one (11) in good yield upon treatment with the bromide reagent applied above. 
For 3,4,5-trimethoxyphenyl-substituted 9c, the preferable reaction path in the Hugerschoff reaction was the 
formation of thiazole ring system 2-(indol-2-carbonylamino)-5,6,7-trimethoxy-benzothiazole (12).  
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Scheme 1 
 
 In order to obtain further analogs, 2-(4-chlorophenylthio)-1,3-thiazino[5,6-b]indole-4-one 15 was also 
prepared (Scheme 2). The reaction of isocyanate 7 with 4-chlorothiophenol provided dithiocarbamate 
derivative 14, which underwent oxidative ring closure reaction providing thiazine 15 when treated with 
phenyltrimethylammonium tribromide. 
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Scheme 2 
 
 The structures of the synthesized compounds were verified by IR, 1H and 13C NMR spectroscopy including 
2D-HMQC, DEPT, 1H,13C and 13C,15N-HMBC measurments. Spectral data are given in Tables 1 and 2. 
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 These techniques provided unambiguous proof of the formation of the expected structures. The only 
exception is compound 12, which formed instead of desired 2-(3,4,5-trimethoxyphenylimino)-1,3-thiazino[5,6-
b]indole-4-one. The benzthiazole moiety in 12 is verified by the following spectral data. 
 The benzene ring bearing the three methoxy substituents is penta-substituted (only a single aromatic 
carbon is protonated). 
 The six benzene carbons have carbon lines with different chemical shifts. 
 The substitution is asymmetric and the three methoxy groups have different 1H and 13C NMR signals. 
 The C-2 atom in the indole moiety is unsubstituted (the appropriate 1H NMR singlet appears at 7.74 
ppm). 
 The ring-chain tautomerism and the N-inversion around the exo sp2 N atom result in slow motion of 
the electron distribution in molecules 10 and 11. Consequently, the carbon lines of S–C= and lactam 
C=O groups have broadened and thus in the 13C NMR spectrum  cannot be assigned in every cases. 
Similarly, the H-2’,6’ signals in the 1H NMR are broadened. Such broadenings are not observed in the 
spectra of 12.  
 It is to be noted that in compounds 9a–c a chelate-type hydrogen bonding can form within the CO-NH-CS 
moiety. (A six-membered ring is formed by H-bonding between the carbonyl oxygen and the SH-hydrogen of 
the CO-N=C-SH tautomeric form). This assumption is supported by the following observations.  
 The νNH IR band of this group is extremely broadened (around 2000 cm–1) and thus hardly observable. 
Such a diffuse absorption band is characteristic of chelates.38 
 The C=S line in 13C NMR appears at 179.5–179.7 ppm for 9a–c, outside the usual interval (173–176 
ppm39). 
 The electron-withdrawing or electron-releasing character of the substituents in the NH-aryl group does 
not have any influence on the IR frequencies and the NMR shifts of the CO-NH-CS group. This makes 
highly probable that these two parts of the molecule (NHAr and CONHCS) are isolated from one 
another. All these features are in good agreement with the presence of the stable chelate ring. 
 
Table 1. Characteristic IR frequenciesa and 1H NMR datab of compounds 9a–c, 10−12 and 15c 
Com- νNH ν(N)C=O γCArH γCArH H−3 H−4 H−5  H−6 H−7 H−2’,6’ H−3’,5’ NH NH 
pound band band band d band e s d ~ d d ~ t d ~ t d ~ d d d (2H)e d/t (2H)e amide indole 
9a 3358 1641 739, 
733 
844, 820 7.83 7.70 7.11 7.31 7.51 7.48 7.73 11.6, 12.0 12.6 
9b 3346, 3294 1658 740 8.46 7.82 7.70 7.11 7.31 7.51 7.93 8.01 11.6, 12.0 12.8 
9c 3390, 
3216 
1649 746 705 7.81 7.70 711 7.31 7.51 7.13 − 11.5, 12.0 12.6 
10 3221 1616 740 828 − 7.67 7.15 7.40 7.53 ~7.6 7.44 11.1 12.4 
11 ~3450 1649 754 716 − 7.68 7.18 7.42 7.56 ~7.7 7.99 ~11.1 12.3 
12 3260 1648 749 810 7.74 7.70 7.10 7.28 7.51 7.17f − 12.9 12.0 
15 3230 1631 743 828 − 7.75
 7.18 7.46 7.58 7.87 7.71 − 12.7 
aIn KBr discs (cm−1). Further bands, Ester: νC=O: 1713 (9b), 1735 (11); νC−O: 1276, 1153 (9b), 1307, 1191 (11), 
νC−O (methoxy groups): 1222, 1125 (9c), 1278, 1110 (12); bIn DMSO-d6 solution at 500 MHz. Chemical shifts in 
ppm (δTMS = 0 ppm). Further signals: CH3 and CH2 (OEt, 9b, 11): 1.34, t, J: 7.1 Hz and 4.34 qa; OCH3, s: 3.69 (9c, 
6H, Pos 3’,5’), 3.80 (9c, 3H, Pos. 4’), 3.80, 3.90, 4.03 (12, 3-3H, Pos. 7’, 6’ and 5’); cAssignments were supported 
by HMQC and 1H,13C HMBC measurements; dIndole ring; eAryl group; f Pos. 4’. 
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Table 2. 
13C NMR chemical shiftsa of compounds 9a–c, 10−12 and 15b  
Com- C=S C=O C−2 C−3 C−3a C−4 C−5 C−6 C−7 C−7a C−1’ C−2’,6’ C−3’,5’ C−4’ 
pound ester amide indole ring aryl group 
9a 179.7 161.9 128.8 109.2 127.3 123.0 120.9 125.8 113.1 138.4 130.8 129.0 126.8 137.5 
9b 179.7 162.3 129.2e 109.7 127.7. 123.4 121.3 126.3 113.5 138.8 143.2 124.5 130.6 128.0 
9c 179.5 162.4 129.3 109.6 127.7 123.4 121.3 126.2 113.5 138.8 134.6 103.05 153.5 136.5 
10 ? 162.2c 123.8  110.9 121.9 120.8 121.4 127.5 114.1 138.4 128.9 123.7 129.9 123.8 
11 ? ? 123.9 111.0 122.0 120.7 121.4 d 127.5 114.2 138.6 126.2 121.5d 131.2 121.5d 
12 158.9e 160.6 129.9 107.4 127.8 123.2 121.2 125.6 113.4 138.4 147.2f 100.2g 145.9h 154.4i 
15 175.4e 160.4 121.5 115.3 123.2 121.3 121.9 128.4 114.3 138.4 123.5 139.3 131.4 137.9 
aIn ppm (δTMS = 0 ppm) at 125.7 MHz. Solvent: DMSO-d6. Further signals, CH3: 15.1 (9b, 11), CH2: 61.6 (9b), 
61.3 (11), 21.8 (11); OCH3 (Pos.. 3,5 and 4): 56.9 and 61.0 (9c), OCH3 (Pos.. 5-7): 57.1, 61.3, 61.8(12); C=O 
(ester): 166.0 (9b), 166.2 (11). Due to slow motion of the NH-C=NAr ⇄ N=C-NHAr moiety (tautomerism) were 
not possible to identify the SC= (10 and 11) and C=O (amide) lines(11); bAssignments were supported by DEPT 
(except for 9a, 11), 2D-HMQC, 1H,13C HMBC, for 12 also by 1H,15N HMBC measurements; cBroadened signal; 
dReversed assignments is also possible; e SC=N line; f/g/h/iC-3a, 4, 5 and 6 lines, resp. in benzthiazole moiety. 
 
 Concerning the ring-chain tautomerism possible in 10–12, the difference in the shape and shift of NH signal 
between 10–11 and 12, respectively, is striking. In 12 the preferred structure of the aromatic benzothiazole 
part excludes the tautomerism and the amide NH signal is sharp and has higher shift at 12.0 ppm. In contrast, 
the tautomeric equilibrium of 10 and 11 results in a broad NH signal and a lower shift (11.1 ppm). 
 
Table 3. In vitro antiproliferative effects of compounds prepared 
Compound Concentr. 
Growth inhibition, % ± SEMa 
HeLa A2780 MCF7 A431 
9a 10 µM – – – n.t. 
 30 µM 47.5 ± 1.7 – 49.2 ± 0.7 n.t. 
9b 10 µM 61.4 ± 0.5 –a – 45.2 ± 0.2 
 30 µM 58.8 ± 1.4 – – 50.2 ± 0.3 
9c 10 µM 35.5 ± 1.8 29.6 ± 1.0 – – 
 30 µM 48.2 ± 2.9 52.0 ± 1.4 31.2 ± 1.9 44.8 ± 0.8 
10 10 µM – 61.5 ± 1.0 44.8 ± 1.4 – 
 30 µM 63.8 ± 0.7 79.1 ± 0.5 70.1 ± 0.8 70.6 ± 0.7 
11 10 µM 61.2 ± 0.9 55.3 ± 1.5 36.0 ± 2.1 67.2 ± 0.8 
 30 µM 81.7 ± 2.4 87.6 ± 1.8 82.3 ± 2.5 81.7 ± 0.6 
12 10 µM – 60.4 ± 1.2 43.3 ± 1.8 – 
 30 µM 89.0 ± 0.9 94.7 ± 0.1 92.5 ± 0.2 68.4 ± 1.1 
15 10 µM 47.1 ± 1.9 89.6 ± 2.1 69.6 ± 1.3 n.t. 
 30 µM 93.0 ± 2.3 95.3 ± 0.4 89.8 ± 0.3 n.t. 
Cisplatin 10 µM 42.6 ± 2.3 83.6 ± 1.2 53.0 ± 2.3 88.5 ± 0.5 
 30 µM 99.9 ± 0.3 95.0 ± 0.3 86.9 ± 1.2 90.2 ± 1.8 
aSubstances eliciting less than 25% inhibition of cell proliferation were regarded as ineffective and the results 
are not presented; n.t.: not tested 
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 The in vitro antiproliferative activities of the compounds prepared were examined on human tumor cell 
lines40 HeLa (cervix adenocarcinoma), MCF7 (breast adenocarcinoma), A2780 (ovarian carcinoma) and A431 
(squamous carcinoma) by means of MTT assay. The results are summarized in Table 3. 
 Modest growth inhibition effects were observed for isocyclobrassinin analogs 9a–c. The ring-closed 4-
arylimino-thiazines 10 and 11 performed moderate cell growth inhibition (up to 67.2%, 10 µM, compound 11, 
A431 cell line). Interestingly, thiazole 12 also has relatively good inhibition effect on cell line A2780 (60.4% at 
10 µM). Of our compounds prepared 2-(4-chlorophenylthio)-4,5-dihydro-1,3-thiazino[5,6-b]indole-4-one 15 
showed the highest antiproliferative activity exhibiting 89.6 % (10 µM ) growth inhibition on cell line A2780. 
This value is comparable to that of cisplatin. 
 
 
Conclusions 
 
In summary, isomeric analogs of cyclobrassinin phytoalexin possessing the 1,3-thiazino[5,6-b]indole-4-one 
skeleton have been prepared, and were found to have noteworthy in vitro antiproliferative effects. The 2-(4-
chlorophenylthio)-4,5-dihydro-1,3-thiazino[5,6-b]indole-4-one derivative 15, a sulfur analogue of β-carboline 
showed the highest antiproliferative activity. The structures of the novel compounds prepared were 
confirmed by means of IR and NMR spectroscopy and discussed in some detail. 
 
 
Experimental Section 
 
General. Melting points were determined on a Kofler micro melting apparatus and are uncorrected. Elemental 
analyses were performed with a Perkin-Elmer 2400 CHNS elemental analyser. Merck Kieselgel 60F254 plates 
were used for TLC, and Merck Silica gel 60 (0.063-0.100) for column chromatography. The 1H and 13C NMR 
spectra were recorded in CDCl3 solution in 5 mm tubes at room temperature, on a Bruker DRX 500 
spectrometer at 500 (1H) and 126 (13C) MHz, with the deuterium signal of the solvent as the lock and TMS as 
internal standard. DEPT spectra were run in a standard manner, using only the Θ = 1350 pulse to separate 
CH/CH3 and CH2 lines phased "up" and "down", respectively. The 2D-HSQC and -HMBC spectra were obtained 
by using the standard Bruker pulse programs. Indole-2-carboxylic acid was purchased from Fluka. Indole-2-
carbonyl chloride was prepared by an earlier method.35 
     The antiproliferative properties of the prepared analogs were determined in vitro against a panel of human 
adherent cancer cell lines40 including HeLa (cervix adenocarcinoma), MCF7 (breast adenocarcinoma), A2780 
(ovarian carcinoma) and A431 (squamous carcinoma). All cell lines were purchased from the European 
Collection of Cell Cultures (ECCAC, Salisbury, UK). The cells were maintained in minimal essential medium 
(Lonza Ltd, Basel, Switzerland) supplemented with 10% foetal bovine serum, 1% non-essential amino acids and 
an antibiotic-antimycotic mixture. Near-confluent cancer cells were seeded onto a 96-well microplate at the 
density of 5000 cells/well and, after overnight standing, new medium (200 μL) containing the tested 
compound at 10 and 30 µM was added. After incubation for 72 h at 37 ºC in humidified air containing 5% CO2, 
the viability of the cells was determined by the addition of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution. During a 4-h contact period, the MTT was converted by intact 
mitochondrial reductase and the precipitated formazan crystals were dissolved in 100 μL DMSO. Finally, the 
reduced MTT was assayed at 545 nm, using a microplate reader; wells with untreated cells were utilized as 
controls. All in vitro experiments were carried out on two microplates with at least five parallel wells. Stock 
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solutions of the tested substances (10 mM) were prepared in DMSO. The highest DMSO content of the 
medium (0.3%) did not have any substantial effect on the cell proliferation. Cisplatin (Ebewe Pharma GmbH, 
Unterach, Austria) was used as the reference agent. 
 
General procedure for the preparation of N-aryl-N’-(1H-indole-2-carbonyl)thioureas (9a–c). To a stirred 
solution of potassium thiocyanate (2.0 g, 20.6 mmol) in dry acetone (30 mL) a solution of freshly prepared 
indole-2-carbonyl chloride (3.4 g, 20,0 mmol) in acetone (10 ml) was added in one portion at room 
temperature. The reaction mixture was stirred for 1 h at room temperature and filtered through a sintered 
glass. After the evaporation of the solvent, the crystalline product was taken up in diethyl ether (2 x 10 mL) and 
filtered. Isothiocyanate (7) was used in the next step without any further purification. 
To the stirred solution of 1H-indole-2-carbonyl isothiocyanate 7 (0.5 g, 2,4 mmol) in acetone (10 mL) the 
appropriately substituted aniline 8a–c derivative was added portionwise. The reaction mixture was stirred at 
room temperature for 1 h (9c precipitated as white crystalline product) and then concentrated. The crystalline 
residues were triturated with acetone (9a–c), filtered off and purified as indicated. 
N-(4-chlorophenyl)-N’-(1H-indole-2-carbonyl)thiourea (9a). A pale-yellow crystalline powder, mp 209–212 ºC 
(methanol) , yield 92%. Anal. Calcd. for C16H12ClN3OS (329.80): C, 58.27; H, 3.67; N, 12.74; S, 9.72. Found: C, 
58.05; H, 3.89; N, 12.55; S, 9.95. 
N-[4-(ethoxycarbonyl)phenyl]-N’-(1H-indole-2-carbonyl)thiourea (9b). A pale-yellow crystalline powder, mp 
212–215 ºC (methanol), yield 87%. Anal. Calcd. for C19H17N3O3S (367.42): C, 62.11; H, 4.66; N, 11.44; S, 8.73. 
Found: C, 62.40; H, 4.81; N, 11.27; S, 8.95. 
N’-(1H-indole-2-carbonyl)-N-(3,4,5-trimethoxyphenyl)thiourea (9c). A pale-yellow crystalline powder, mp 
208–210 ºC (methanol+chloroform), yield 93%. Anal. Calcd. for C19H19N3O4S (385.44): C, 59.21; H, 4.97; N, 
10.90; S, 8.32. Found: C, 59.07; H, 5.21; N, 10.67; S, 8.61. 
 
General procedure for the preparation of 4,5-dihydro-1,3-thiazino[5,6-b]indole-4-one derivatives (10, 11) 
and benzothiazole (12). To an intensively stirred suspension of thiourea derivatives 9a–c (0.7 mmol) in 
dichloromethane (20 mL), phenyltrimethylammonium tribromide (0.26 g, 0.69 mmol) was added in one 
portion at room temperature. After stirring for 5 min, triethylamine (0.39 mL, 2. 8 mmol) was added in one 
portion to the clear solution. The solvent was evaporated (water bath <50 °C) and the residue was purified by 
column chromatography, using n-hexane/ethyl acetate 3:2 as an eluent, to give 10–12 as crystalline powders. 
2-(4-Chlorophenylimino)-4,5-dihydro-1,3-thiazino[5,6-b]indole-4-one (10). A yellow crystalline powder, mp 
302–305 ºC, yield 78%. Anal. Calcd. for C16H10ClN3OS (327.79): C, 58.63; H, 3.08; N, 12.82; S, 9.78. Found: C, 
58.38; H, 3.27; N, 12.57; S, 10.05. 
2-[(4-(Ethoxycarbonyl)phenylimino]-4,5-dihydro-1,3-thiazino[5,6-b]indole-4-one (11). A yellow crystalline 
powder, mp 289–291 ºC, yield 81%. Anal. Calcd. for C19H15N3O3S (365.41): C, 62.45; H, 4.14; N, 11.50; S, 8.78. 
Found: C, 62.28; H, 4.40; N, 11.33; S, 9.05. 
2-(Indole-2-carbonylamino)-5,6,7-trimethoxy-benzothiazole (12). A pale-yellow crystalline powder, mp 258–
261 ºC, yield 84%. Anal. Calcd. for C19H17N3O4S (383.42): C, 59.52; H, 4.47; N, 10.96; S, 8.36. Found: C, 59.77; H, 
4.67; N, 10.75; S, 8.24. 
 
General procedure for the preparation of 2-(4-chlorophenylthio)-4,5-dihydro-1,3-thiazino[5,6-b]indole-4-one 
(15). To a stirred solution of acyl isothiocyanate 7 (0.5 g, 2,4 mmol) in acetone (10 mL) thiophenol 13 derivative 
was added portionwise. The reaction mixture was stirred at room temperature for 1 h and then concentrated. 
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The crystalline residue was triturated with diisopropylether+ethyl acetate. Product 14 was filtered off and used 
without further purification in the next ring-closing step. 
To an intensively stirred suspension of thiourea derivative 14 (0.7 mmol) in dichloromethane (20 mL), 
phenyltrimethylammonium tribromide (0.26 g, 0.69 mmol) was added in one portion at room temperature. 
After stirring for 5 min, triethylamine (0.39 mL, 2. 8 mmol) was added in one portion to the clear solution. The 
solvent was evaporated (water bath <50 °C) and the residue was purified by column chromatography, using n-
hexane/ethyl acetate 3:2 as an eluent, to give 15 as a yellow crystalline powder, mp 288–290 ºC, yield 67%. 
Anal. Calcd. for C16H9ClN2OS2 (344.84): C, 55.73; H, 2.63; N, 8.12; S, 18.60. Found: C, 55.93; H, 2.82; N, 8.33; S, 
18.76 
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